Palvella Therapeutics Inc... (PVLA)
29.00
1.01 (3.61%)
At close: Mar 12, 2025, 3:59 PM
36.37
25.41%
After-hours: Mar 12, 2025, 07:56 PM EDT
3.61% (1D)
| Bid | 27.6 |
| Market Cap | 325.42M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | n/a |
| EPS (ttm) | 1.97 |
| PE Ratio (ttm) | 14.72 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 45.14 |
| Volume | 84,619 |
| Avg. Volume (20D) | 48,658 |
| Open | 27.88 |
| Previous Close | 27.99 |
| Day's Range | 27.16 - 29.09 |
| 52-Week Range | 6.20 - 29.09 |
| Beta | -23.17 |
About PVLA
Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. Its lead product candidate is QTORIN 3.9% rapamycin anhydrous gel (QTORIN rapamycin) that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformations. It als...
Industry Biotechnology
Sector Healthcare
IPO Date Jan 2, 2015
Employees NaN
Stock Exchange NASDAQ
Ticker Symbol PVLA
Website https://palvellatx.com
Analyst Forecast
According to 4 analyst ratings, the average rating for PVLA stock is "Buy." The 12-month stock price forecast is $41.5, which is an increase of 43.10% from the latest price.
Stock Forecasts1 month ago
+6.26%
Palvella Therapeutics shares are trading higher af...
Unlock content with
Pro Subscription